Table 2.

Risk stratification system (CCCG-HB-2016)⁶

Risk group		AFP (ng/mL)	PRETEXT staging system	COG staging system	Pathological type	P+/V+/M+/E+/H+/N+	Note
Very low risk				Stage I	Differentiated PFH		Both met simultaneously.
Low risk	1	≥100	Stage I/II			None	All met simultaneously.
	2			Stage I/II	Non-PFH and non-SUC		Both met simultaneously.
Intermediate risk	1		Stage III
	2			Stage I/II	SUC		Both met simultaneously.
	3			Stage III
High risk	1	<100					Satisfy any of them.
	2		Stage IV
	3			Stage IV
	4					P+/V+

AFP, alpha fetoprotein; CCCG-HB-2016, Chinese Anti-Cancer Association Pediatric Committee Hepatoblastoma consensus 2016; COG, Children’s Oncology Group; E+, extrahepatic and intra-abdominal diseases; H+, liver rupture or intraperitoneal bleeding; HB, hepatoblastoma; M+, instant metastasis; N+, lymph node involvement; P+, portal vein invasion; PFH, pure fetal histology; PRETEXT, PRE Treatment EXTent of disease; SUC, small cell undifferentiated; V+, inferior vena cava or hepatic vein invasion.